JANUMET (sitagliptin and metformin hydrochloride) by Merck & Co. is 2 diabetes mellitus: sitagliptin, a dipeptidyl peptidase-4 (dpp-4) inhibitor, and metformin hcl, a member of the biguanide class. First approved in 2007.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
JANUMET is a fixed-dose combination tablet containing sitagliptin (a DPP-4 inhibitor) and metformin HCl (a biguanide) approved by the FDA in March 2007 for the treatment of type 2 diabetes mellitus. Sitagliptin works by inhibiting dipeptidyl peptidase-4 to prolong the action of incretin hormones (GLP-1 and GIP), thereby increasing insulin release and decreasing glucagon levels in a glucose-dependent manner. Metformin improves insulin sensitivity and reduces hepatic glucose production and intestinal glucose absorption. JANUMET represents a foundational combination therapy in the type 2 diabetes treatment armamentarium, typically positioned as a second-line agent when monotherapy is insufficient.
2 diabetes mellitus: sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin HCl, a member of the biguanide class. Sitagliptin Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones.…
Worked on JANUMET at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)
Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moMerck & Co. is hiring 8 roles related to this product
LOE in ~3 years — strategic planning for patent cliff underway
$799M Medicare spend — this is a commercially significant brand
JANUMET supports commercial roles including brand management, field sales representatives, and medical science liaisons focused on endocrinology and primary care segments. Success on this product requires deep expertise in type 2 diabetes treatment algorithms, comparative effectiveness messaging against SGLT-2 inhibitors and GLP-1 agonists, and renal safety considerations. Currently, there are 0 linked open job positions associated with this product, reflecting the mature market stage and approaching loss of exclusivity, with hiring likely to decline further as LOE approaches.